Webb1 nov. 2024 · Background & Aims. We report data from two similarly designed studies that evaluated the efficacy, safety, and optimal duration of ledipasvir/sofosbuvir (LDV/SOF) ± ribavirin (RBV) for retreatment of chronic hepatitis C virus (HCV) in individuals who failed to achieve sustained virological response (SVR) with prior SOF-based, non-NS5A inhibitor … Webb1 jan. 2024 · Conflict of Interest and Sources of Funding: Dr. Haubrich is Professor Emeritus at UCSD and a current employee of Gilead Sciences. Dr. Daar receives research …
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir ...
WebbView Richard Haubrich's business profile as Vice President, Medical Affairs at Gilead. Find contact's direct phone number, email address, work history, and more. Leads by Industry Webb1 nov. 2024 · Background & Aims. We report data from two similarly designed studies that evaluated the efficacy, safety, and optimal duration of ledipasvir/sofosbuvir (LDV/SOF) ± … flow bgm
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals …
Webb7 aug. 2024 · R.H.H. is an employee of Gilead. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Author contributions. R.J.L. and C.S.B. devised the project and analysis. Webb9 mars 2024 · Juan Berenguer reports personal fees from Janssen, and grants and personal fees from Gilead, MSD, and ViiV, outside the submitted work. Michelle L. … WebbBerend J. van Welzen9, Lucy Williams2,10, Richard Haubrich 11, Marion Heinzkill 12, Sabrinel Sahali13, Sandra Schreiber12, Joshua Gruber11, Cal Cohen11, Heribert Ramroth2, Stefan Esser14. Longitudinal Analysis of Weight Change in HIV-1 Treatment-Naïve and -Experienced People Living With HIV (PLWH) Initiating/Switching to an NNRTI - or INSTI … flow bid lot winston